Vanguard Portfolio Management
CYTK icon

Vanguard Portfolio Management’s Cytokinetics CYTK Stock Holding History

Vanguard Portfolio Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$572M Buy
6,711,799
+868,017
+15% +$62.3M 0.03% 659
2026
Q1 		$385M Buy
+5,843,782
New +$371M 0.02% 771

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's CYTK Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Cytokinetics (CYTK) stake by 15% in Q2 2026, buying an estimated $62.3M and bringing the position to 6,711,799 shares worth $572M. The position accounts for 0.03% of the portfolio, ranked #659.

Vanguard Portfolio Management first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 447 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Portfolio Management held 6,711,799 shares of Cytokinetics worth $572M as of Q2 2026.
  • Vanguard Portfolio Management bought 868,017 Cytokinetics shares in Q2 2026, an estimated $62.3M.
  • Cytokinetics made up 0.03% of Vanguard Portfolio Management's portfolio in Q2 2026, its #659 holding.
  • Vanguard Portfolio Management first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 447 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.